Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SCHERING-PLOUGH

(SGP)
SummaryNewsCompany 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

SCHERING-PLOUGH : to Appeal Jury Decision in Missouri Reimbursement Case

10/30/2008 | 04:29pm EST

ST. LOUIS, Oct. 30 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) said today that it strongly believes that the decision reached by a jury in Missouri related to reimbursement by Missouri's Medicaid program of certain products sold by Warrick Pharmaceuticals, the company's former generics subsidiary, was incorrect. The company said it will appeal and continues to maintain that it complied with all applicable laws and regulations governing reimbursement rules in Missouri.

The company has prevailed in two other reimbursement cases.

In November 2007, the U.S. District Court for the District of Massachusetts found no liability for Warrick Pharmaceuticals in a class action lawsuit involving several pharmaceutical companies and the setting of average wholesale prices (AWPs) for prescription products. In that case, the Court issued favorable rulings for the company and dismissed all claims relating to Schering-Plough's branded pharmaceutical products and Warrick's generic albuterol sulfate solution. The Court entered judgment in favor of Schering-Plough based on its ruling that Schering's AWP were not inflated and entered judgment in favor of Warrick based on its findings that Warrick's AWP had no effect on Medicare reimbursement and resulted in no damages to class plaintiffs.

In December 2005, a West Virginia jury ruled in favor of the company in a trial related to reimbursement by West Virginia's Medicaid program of certain asthma products sold by Warrick Pharmaceuticals. In the favorable verdict, the jury agreed with the company's position that in connection with reporting AWP the company complied with all applicable laws and regulations governing the reimbursement rules in West Virginia.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.

SOURCE Schering-Plough Corporation


ę PRNewswire 2008
All news about SCHERING-PLOUGH
2009SCHERING-PLOUGH : Announces Sponsorship of Rabies-Control Projects in India
PR
2009SCHERING-PLOUGH : Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary En..
PR
2009SCHERING-PLOUGH : U.S. Food and Drug Administration Issues Complete Response Letter Regard..
PR
2009SCHERING-PLOUGH : Standard & Poor's Announces Changes to U.S. Indices
PR
2009SCHERING-PLOUGH : Reports Financial Results for 2009 Third Quarter
PR
2009SCHERING-PLOUGH : Nobilon Advances Intranasal Seasonal Influenza Vaccine Into Proof of Con..
PR
2009SCHERING-PLOUGH : Schedules Conference Call Webcast For 2009 Third Quarter Earnings
PR
2009SCHERING-PLOUGH : SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcu..
PR
2009SCHERING-PLOUGH : Declares Quarterly Dividends on Common Shares and Mandatory Convertible ..
PR
2009SCHERING-PLOUGH : Reports Long-Term Vicriviroc Data From Phase II Open-Label Extension Stu..
PR
More news